Revision received August 29, 2000. Rerevision received October 9, 2000.
Accepted October 16, 2000.
Address all correspondence and requests for reprints to: F. P. M. Kruijver,
M.D., or D. F. Swaab, M.D., Ph.D., Netherlands Institute for Brain Research, Meibergdreef
33, 1105 AZ Amsterdam, The Netherlands. E-mail: f.kruijver@nih.knaw.nl.
*
Sabbatical stay in The Netherlands partially supported by a grant from
CONACyT (Grant 971017).
Copyright © 2001 by The Endocrine Society
ABSTRACT
In a previous study we found androgen receptor (AR) sex differences in several
regions throughout the human hypothalamus. Generally, men had stronger nuclear AR
immunoreactivity (AR-ir) than women. The strongest nuclear labeling was found in
the caudal hypothalamus in the mamillary body complex (MBC), which is known to be
involved in aspects of cognition and sexual behavior. The present study was carried
out to investigate whether the sex difference in AR-ir of the MBC is related to sexual
orientation or gender identity ( i.e. the feeling
of being male or female) or to circulating levels of androgens, as nuclear AR-ir
is known to be up-regulated by androgens. Therefore, we studied the MBC in postmortem
brain material from the following groups: young heterosexual men, young homosexual
men, aged heterosexual castrated and noncastrated men, castrated and noncastrated
transsexuals, young heterosexual women, and a young virilized woman. Nuclear AR-ir
did not differ significantly between heterosexual and homosexual men, but was significantly
stronger than that in women. A female-like pattern of AR-ir ( i.e.
no to weak nuclear staining) was observed in 26- to 53-yr-old castrated male-to-female
transsexuals and in old castrated and non-castrated men, 67-87 yr of age. In
analogy with animal studies showing strong activational effects of androgens on nuclear
AR-ir, the present data suggest that nuclear AR-ir in the human MBC is dependent
on the presence or absence of circulating levels of androgen. The group data were,
moreover, supported by the fact that a male-like AR-ir ( i.e.
intense nuclear AR-ir) was found in a 36-yr-old bisexual noncastrated male-to-female
transsexual and in a heterosexual virilized woman, 46 yr of age, with high levels
of circulating testosterone. In conclusion, the sexually dimorphic AR-ir in the MBC
seemed to be clearly related to circulating levels of androgens and not to sexual
orientation or gender identity. The functional implications of these alterations
are discussed in relation to reproduction, cognition, and neuroprotection. ( J
Clin Endocrinol Metab
86: 818-827, 2001)
IN ANALOGY WITH the nonhuman vertebrate brain [1]
[2]
, it is thought that in the human also the interaction
between sex hormones and their receptors may play an important role in brain development
(organizing effects) and may in adulthood alter brain function (activating effects),
and that these two mechanisms lead to sex differences in behavior in adult life.
Structural and functional sex differences in the brain may be related to reproduction,
sexual orientation, gender identity ( i.e. the feeling
of being male or female), cognition, and disease [3]
[4]
. In a number of areas of the human hypothalamus,
structural and functional differences between the sexes and between homosexual and
heterosexual men have been described [5]
[6]
[7]
. In addition, our group has found that the central
part of the bed nucleus of the stria terminalis (BSTc) is sexually dimorphic, i.e.
smaller in women, with a female volume and neuron number in male-to-female transsexuals
[4]
[8]
.
It has been shown that various areas of the preoptic area (POA) [9]
[10]
, BST [11]
and suprachiasmatic nucleus [12]
[13]
are larger in men than in women, whereas the
opposite was found for the anterior commissure [14]
.
Moreover, hypothalamic differences in relation to sexual orientation have been observed.
The suprachiasmatic nucleus [15]
and the anterior
commissure [16]
are larger in homosexual than in
heterosexual men, whereas the interstitial nucleus of the anterior hypothalamus-3
is smaller in homosexual than in heterosexual subjects [17]
.
These data together with the abundant information showing that sexual orientation
and gender identity do not vary with adult endocrine changes [18]
[19]
suggest that any possible clue to understanding
the biological basis of sex differences, sexual orientation, or gender identity will
require careful analysis of a large number of brain areas.
Recently we found that in a number of hypothalamic areas men showed stronger
androgen receptor (AR) immunoreactivity (AR-ir) than women. Interestingly, in the
anterior hypothalamus only moderate sex differences were found, whereas a conspicuous
sex difference occurred in the posterior hypothalamus, i.e.
the medial mamillary nucleus (MMN) and lateromamillary nucleus (LMN) of the mamillary
body (MB) complex (MBC) [20]
. Such sexual dimorphisms
may be related to gender differences in certain aspects of reproduction or sexual
behavior, as various studies
Recipient of a grant from the NWO (Grant 903-47004).
showed that lesions in the rat
MB produced a complete loss of sexual activity [21]
.
Moreover, electrical stimulation of this area in squirrel monkeys induces penile
erection [22]
[23]
. In addition, Lisk [24]
reported in 1967 that implanting testosterone into the MBC of male castrated rats
restored sexual excitability in the presence of receptive females (see also Refs.
[25]
and [26]
).
These data suggest that this area participates in the control of male sexual motivation.
In contrast, in the female rat, Galindo-Estaun [27]
showed that lesioning the MB did not alter the estrous cycle or alter sexual or maternal
behavior.
The present study was carried out to investigate whether the sex difference
in nuclear AR-ir of the human MBC is related to sexual orientation, gender identity,
or endocrine status. In many species, castration strongly reduces or even eliminates
nuclear AR-ir, whereas testosterone, but not estrogen, injection restores such strong
nuclear AR-ir [28]
[29]
[30]
. As nuclear AR-ir is up-regulated by androgens
[28]
[31]
[32]
, we would expect decreased AR-ir in castrated/aged
men. Therefore, we studied AR-ir in the MBC in groups of subjects with different
testosterone levels [33]
[34]
, i.e. young
heterosexual men/young homosexual men, young heterosexual women, aged heterosexual
castrated and noncastrated men, and castrated and noncastrated transsexuals.
Subjects and Methods
Subjects
In the present study we included the area of the MBC from the posterior hypothalamus
of the following 47 patients: 1) young heterosexual men (n = 9), 2) young homosexual
men (n = 10), 3) old hetero sexual castrated men (n = 5), 4) castrated male-to-female
transsexuals (n = 6), 5) old heterosexual intact men (n = 5), 6) young heterosexual
women (n = 8), 7) a 36-yr-old noncastrated male-to-female transsexual, 8) a nontreated
84-yr-old male subject with strong cross-gender identity feelings, 9) a 51-yr-old
female-to-male transsexual, and 10) a 46-yr-old woman with high levels of androgens.
Brains were obtained by autopsy (for clinicopathological information and ages,
see
Table 3
). Unless stated otherwise, patients
had no primary neurological or psychiatric diseases. The sexual orientation of the
subjects was presumed to be heterosexual [15]
unless
stated otherwise, whereas the sexual orientation of the homosexual group was documented
in the clinical records [15]
. All homosexual patients
died of acquired immunodeficiency syndrome or related diseases. The patient data
have previously been reported [15]
. General pathology
and neuropathology were performed either at the Free University of Amsterdam (Dr.
W. Kamphorst, Prof. F. C. Stam or Prof. P. van der Valk) or at the Academic Medical
Center of the University of Amsterdam (Dr. D. Troost). The subjects had no primary
endocrine illnesses, except for those who had undergone orchidectomy, had been given
hormonal treatment, or had had abnormal hormone fluctuations that are mentioned in
Table 2
. The pathologically high levels of
androgens in a 46-yr-old woman, [androstenedione, 48.0 ng/mL (normal values for women,
0.4-3.5 ng/mL); testosterone, 26.82 nmol/L (normal values for women, 1.04-3.30
nmol/L)] were due to an adrenal cortex carcinoma.
Histology and immunohistochemistry
After autopsy, the hypothalamus was fixed for about 1 month in 4% formaldehyde
at room temperature, dehydrated, and embedded in paraffin. Serial 6-mum frontal
sections were cut on a Leitz microtome (Rockleigh, NJ).
The immunohistochemical protocol followed for the AR staining has been previously
described in detail [20]
. Briefly, this protocol
consisted of mounting paraffin-embedded sections of the posterior hypothalamus onto
SuperFrost Plus (Menzel, Darmstadt, Germany) slides. The sections were deparaffinized
and rehydrated in a series of ethanol concentrations. To retrieve antigenicity, sections
were microwaved (10 min at 700 watts) in 0.1 mol/L citric acid monohydrate buffer
(pH 6.0) [35]
[36]
, after which they were rinsed with TBS buffer
(0.05 mol/L Tris-0.9% NaCl, pH 7.6). To decrease background, the slides were preincubated
for 1 h with TBS-milk [5% milk-TBS solution with commercially available powdered
milk (ELK, Campina Melkunie, Eindhoven, The Netherlands)] before incubation with
the primary antibody PG21 (donated by Drs. Gail Prins and Geoffrey Greene; 1:1000)
for 1 h at room temperature and subsequently kept overnight at 4 C. After rinsing
in TBS-milk buffer, sections were incubated for 1 h with a goat antirabbit biotinylated
second antibody (1:200), followed by another hour of incubation in the avidin-biotin
complex (1:800). The subsequent signal amplification method consisted of an incubation
in biotinylated tyramine (1:1000) and 0.01% peroxide (Merck & Co., Darmstadt,
Germany) for 20 min [37]
. Thereafter, sections were
rinsed with TBS, and the avidin-biotin complex procedure was repeated. After rinsing
in 0.05 mol/L Tris-HCl (pH 7.6), slides were developed by incubation for 10 min in
0.05 mol/L Tris-HCl containing 0.05% 3,3
-diaminobenzidine (Sigma, St. Louis,
MO), 0.01% hydrogen peroxide, and 0.3% nickel ammonium sulfate. Developed sections
were dehydrated in alcohol, cleared with xylene, and coverslipped with Entallan (Merck
& Co.).
Analysis of AR staining intensity
The sections were rated for staining intensity by three independent investigators
blind to the details of the patients. The few differences in rating were concurred
by settlement [20]
. The category assigned to the
MMN and LMN corresponded to the predominant cell type within that area according
to the following scale: 0 = no staining, 1 = staining diffuse and transparent, and
2 = intense staining with individual granules of the reaction product distinguishable.
The staining range was established for both the cytoplasm and the nucleus. The estimates
were made at three different microscopic magnifications: ×2.5, ×10, and
×40 objectives [20]
. The identification of
MMN and LMN was made with the aid of maps of coronal sections of the human brain
published by Mai et al.
[38]
and using alternating thionine-stained sections
for orientation.
Statistics
The assigned categories of AR-ir in the MMN and LMN were compared using the
Kruskal-Wallis ANOVA, followed by the Mann-Whitney U test. The fixation time and
postmortem delay were analyzed by the Kruskal-Wallis test. Differences were considered
statistically significant at P < 0.05 (two-tailed).
Results
Staining specificity
Negative controls, i.e. without the first antibody,
and positive control sections, i.e. tissue of mouse
testes and human anterior
Figure 1. Photomicrographs showing AR-ir in neurons of the MMN of the mamillary body
of a heterosexual man (A), a heterosexual woman (B), a homosexual man (C), and a
woman with high levels of androgens (D). Note that in the mamillary body there is
a clear sex difference in AR-ir (see A and B), whereas there is no difference in
the intensity of AR staining between the representative heterosexual man (A), the
homosexual man (C), and the virilized (androgenized) woman (D). Scale
bar, 150 mum.
pituitary, were run parallel with the hypothalamic sections. Literature
data have shown the specificity of the anti-AR antibody for brain immunohistochemical
studies [29]
[30]
[31]
[39]
[40]
. The specificity data we have added [20]
are briefly described below (data not shown). Omitting the AR antibody PG21 totally
prevented staining. Paraffin-embedded sections of formalin-fixed mouse and human
testes showed clear AR staining in the peritubular cells as previously reported
[41]
[42]
. In the human anterior pituitary isolated groups
of cells with moderate to strong AR-ir were observed, as has also been reported in
the Brazilian opossum [43]
and rat [42]
.
An adsorption test, including an immunoblotting analysis for PG21 with a peptide
that consisted of the first 20 amino acids of the peptide that is recognized by PG21,
showed the expected concentration gradient
on nitrocellulose
paper [the technique has been described by Van der Sluis et
al.
[44]
]. After adsorption of the PG21 antibody with
its corresponding peptide, nuclear and cytoplasmic stainings were completely eliminated
[20]
.
Staining pattern
ANOV As for fixation time and postmortem delay among the heterosexual men,
heterosexual women, homosexual men, and castrated transsexual men did not exhibit
statistically significant differences ( P > 0.1 and
P > 0.9, respectively).
The immunohistochemical staining for AR in the MMN and LMN revealed cells with
nuclear or cytoplasmic labeling or with both types of staining (
Tables 1
and 3
and Figs. 1,
2,
and 3
).
The heterosexual men showed strong nuclear AR-ir in both brain regions (
Tables 1
and 3
and Fig. 1A
). In contrast, the women revealed
much less intense labeling in the nucleus of neurons of the LMN and MMN (
Tables 1
and 3
and Fig. 2B
). This sex difference was statistically
significant for nuclear staining in both areas ( P
< 0.05). The homosexual men showed a similar staining to that of the heterosexual
men for both areas ( P > 0.2) with a more moderate
staining in the MMN (
Tables 1
and 3
and Fig. 1C
). Women differed significantly
from homosexual men in nuclear AR-ir in both the MMN and LMN ( P
< 0.05). The castrated male-to-female transsexual group had a lack of nuclear
staining in both brain areas, but had cytoplasmic labeling in the LMN and MNN (
Tables 1
and 3
and Fig. 2B
). This group was statistically
different in the LMN from the heterosexual and homosexual men group ( P
< 0.05) and similar to that in women ( P > 0.5).
The castrated male-to-female transsexual group had significantly less nuclear AR-ir
in the MMN than the heterosexual male group ( P <
0.05). This difference showed only a trend when compared with homosexual men ( P
= 0.10). When
Figure 2. Illustration of the staining intensity of nuclear AR-ir in neurons of a noncastrated
36-yr-old male-to-female transsexual (A) compared with the lack of such staining
in a 26-yr-old castrated male-to-female transsexual. Scale bar,
150 mum.
compared with women, the castrated male-to-female transsexual group did
clearly not differ from women in the MMN ( P > 0.7).
In the 36-yr-old noncastrated male-to-female transsexual, strong nuclear and
cytoplasmic staining was observed in both areas (
Fig. 2A
). Similarly, the 46-yr-old woman
with high levels of androgens revealed strong nuclear labeling and weak to intermediate
cytoplasmic labeling in the LMN and MMN (
Fig. 1D
). The female-to-male transsexual
who did not receive androgen replacement therapy during the last 3 yr before death
(
Table 2
) showed less intense nuclear and
weak to intermediate cytoplasmic staining in both the LMN and MMN.
The results of staining in the posterior hypothalamus of old patients are illustrated
in
Fig. 3 (A and B)
. In old castrated heterosexual
men almost no nuclear and weak cytoplasmic AR-ir were found (
Table 3
and Fig. 3B
). Thus, in this group of five,
two subjects had very weak nuclear and cytoplasmic AR-ir in both areas, whereas three
of five had no nuclear but weak cytoplasmic AR-ir (
Table 3
and Fig. 3B
). A similar trend of weak AR
staining with more, but less intense, nuclear AR-ir was observed in five old intact
men (
Table 3
and Fig. 3A
). In this group four of five
of the individuals had very weak nuclear as well as cytoplasmic AR-ir (
Table 3
). Between the castrated old men and
the intact old men no statistical significant differences were found.
Discussion
The present study confirms the clear sex differences in nuclear AR-ir expression
in neurons of the MBC [20]
and shows, for the first
time, that this sex difference is related to circulating levels of testosterone rather
than to sexual orientation or gender identity.
TABLE 2 -- Patient data
|
Male to female transsexuals (n
= 7 with 6 orchiectomized subjects) |
|
Patient no. (NBB) |
Age (yr) |
|
Age of hormonal treatment/-orchiectomy |
|
Transsexual (84020) |
50 |
42 |
44 |
|
Hormone treatment |
|
|
|
|
Age 42: stilbestrol (5 mg
1 dd); after 2 months to 5 mg 2 dd); age 44: CPA (50 mg 2 dd; treatment lasted 4
yr; stopped 2 yr before death); ethinyloestradiol (50 mug 2 dd; treatment lasted
8 yr until death) |
|
Cause of death: suicide |
|
|
|
|
Patient no. (NBB) |
Age (yr) |
|
Age of hormonal treatment/-orchiectomy |
|
Transsexual (88064) |
43 |
36 |
39 |
|
Hormone treatment |
|
|
|
|
Age 36: received standard CPA treatment
(50 mg 2 dd) until 2 yr before death; at age 39 received standard ethinyl estradiol
treatment (50 mug 2 dd) that stopped 3 months before death! |
|
Cause of death: sarcoma, right side
temporal |
|
|
|
Patient no. (NBB) |
Age (yr) |
|
Age of hormonal treatment/-orchiectomy |
|
Transsexual (93042) |
36 |
NA |
no orchiectomy, testes atrophy |
|
Hormone treatment |
|
|
|
|
CPA (50 mg 1 dd) at least the last
10 months before death; the patient did receive estradiol in combination with hydroxyprogesterone
in therapeutic dosages. Exact period of treatment is not known but based on the significant
testes atrophy she was probably treated for about 5 yr or more. |
|
Cause of death: AIDS, pneumonia,
pericarditis, cytomegaly in brain |
|
|
Patient no. (NBB) |
Age (yr) |
|
Age of hormonal treatment/-orchiectomy |
|
Transsexual (93070) |
53 |
40 |
50 |
|
Hormone treatment |
|
|
|
|
Age 40: stilbestrol treatment (stopped
after 1 yr); at age 43-47: premarin (0.625 mg dd); at age 47-50: Premarin
(3.75 mg dd); at age 50-53: Premarin (2.5 mg 3 dd); CPA (50 mg 1 dd); topical
estrogen cream (estrogen treatment stopped 3 months before death)!!! |
|
Cause of death: acute fatty liver
due to alcohol abuse |
|
|
|
Patient no. (NBB) |
Age (yr) |
|
Age of hormonal treatment/-orchiectomy |
|
Transsexual (95018) |
48 |
35 |
36 |
|
Hormone treatment |
|
|
|
|
Age 35: spironolactone (100 mg 2
dd); CPA (50 mg 2 dd); ethinyl estradiol (50 mug 2 dd); at age 36-40: CPA
(50 mg 2 dd); ethinyl estradiol (50 mug 2 dd); at age 40-48: aldoctone (100
mg 1 dd); ethinyl estradiol (50 mug 1 dd; treatment lasted until death) |
|
Cause of death: Cardiovascular death |
|
|
|
Patient no. (NBB) |
Age (yr) |
|
Age of hormonal treatment/-orchiectomy |
|
Transsexual (98334) |
26 |
23 |
24 |
|
Hormone treatment |
|
|
|
|
Age 23: received standard CPA treatment
(50 mg 2 dd) and ethinyl estradiol (50 mug 2 dd) treatment until death |
|
Cause of death: Suicide |
|
|
|
|
Patient no. (NBB) |
Age (yr) |
|
Age of hormonal treatment/-orchiectomy |
|
Transsexual (98141) |
74 |
64 |
64 |
|
Hormone treatment |
|
|
|
|
Age 64: received standard
CPA treatment (50 mg 2 dd) and ethinyl estradiol (50 mug 2 dd) treatment; at age
67: received estraderm (100 mg 1 dd); at age 74 received spironolacton (50 mg 1 dd)
and estraderm (100 mg 1 dd) |
|
Cause of death: coma after appendicitis,
pneumonia, lung embolism, and occipital cerebral infarction |
|
Nontreated male with cross-gender
identity feelings (n = 1) |
|
|
|
Patient no. (NBB) |
Age (yr) |
|
Age of hormonal treatment/-orchiectomy |
|
(96088) |
84 |
-- |
no orchiectomy or sex reassignment therapy |
|
Hormone treatment |
|
|
|
|
Male patient with strong
cross-gender identity feelings who did not receive sex hormone replacement therapy |
|
Cause of death: lung carcinoma |
|
|
|
Female to male transsexual (n =
1) |
|
|
|
Patient no. (NBB) |
Age (yr) |
|
Age of hormonal treatment/-ovariectomy |
|
(98138) |
51 |
27 |
28 |
|
Hormone treatment |
|
|
|
|
At age 27 testosterone,
Sustanon (250 mg), twice a month injections; at age 30 testosterone undecanoate (40
mg 3 dd); at age 34 testosterone undecanoate (40 mg 2 dd); at age 36 testosterone
undecanoate (40 mg 4 dd); at age 44 testosterone, Sustanon (250 mg) twice a month
injections; at age 47-48 testosterone, Sustanon (250 mg) every 3 weeks From
age 48 until death [51]
no testosterone replacement
therapy! |
|
Cause of death: cachexia |
|
|
|
|
Castrated males (n = 5) |
|
|
|
|
Patient no. (NBB) |
Age (yr) |
|
Age of hormonal treatment/-orchiectomy |
|
(94090) |
86 |
85 |
85 |
|
Hormone treatment |
|
|
|
|
Male patient with prostate cancer;
orchiectomy 20 months before death; patient received an additional antiandrogen therapy,
Androcur (50 mg 4 dd) during the first 14 months, 50 mg 2 dd during the last 6 months) |
|
Cause of death: septic shock with
lung and prostate carcinoma |
|
|
Patient no. (NBB) |
Age (yr) |
|
Age of hormonal treatment/-orchiectomy |
|
(94109) |
82 |
-- |
82 |
|
Hormone treatment |
|
|
|
|
Male patient with prostate
cancer; orchiectomy 20 days before death; patient did not receive additional antiandrogen
therapy |
|
Cause of death: respiratory insufficiency,
prostate carcinoma, renal insufficiency |
|
Patient no. (NBB) |
Age (yr) |
|
Age of hormonal treatment/-orchiectomy |
|
(95062) |
80 |
-- |
75 |
|
Hormone treatment |
|
|
|
|
Male patient with prostate
cancer; orchiectomy 5 yr before death; patient did not receive additional antiandrogen
therapy |
|
Cause of death: renal insufficiency
with metabolic |
|
|
|
Patient no. (NBB) |
Age (yr) |
|
Age of hormonal treatment/-orchiectomy |
|
(97157) |
69 |
67 |
67 |
|
Hormone treatment |
|
|
|
|
Male patient with prostate
cancer; orchiectomy 3 yr before death; patient received anandron (150 mg 1 dd) during
the last 3 yr before death. |
|
Cause of death: prostate cancer
with metastases |
|
|
|
Patient no. (NBB) |
Age (yr) |
|
Age of hormonal treatment/-orchiectomy |
|
(89103) |
67 |
-- |
67 |
|
Hormone treatment |
|
|
|
|
Male patient with prostate
cancer; orchiectomy 3 months before death; patient did not receive additional antiandrogen
therapy |
|
Cause of death: carcinoma of pancreas
with multiple metastases; cachexia |
|
|
Virilized syndrome |
|
|
|
|
Patient no. (NBB) |
Age (yr) |
|
Age of hormonal treatment/-orchiectomy |
|
(83004) |
46 |
-- |
44 |
|
Hormone treatment |
|
|
|
|
Female patient with
a virilizing adrenocortical carcinoma for >1 yr that produced high levels of cortisol,
androstendione, and testosterone levels; latest androstendione serum level before
death was 48.0 ng/mL (normal range for women 0.4-3.5 ng/mL); the latest serum
testosterone level before death, 26.82 nm/L (normal range for women is 1.04-3.30
nm/L). |
|
Cause of death: adrenocorticocarcinoma;
postoperative hemorrhage |
|
|
NBB, patient number of The Netherlands
Brain Bank; T, male-to-female transsexual; CPA, cyproterone acetate; NA, not available;
AIDS, acquired immune deficiency syndrome. |
Heterosexual and homosexual men had the most intense nuclear AR-ir in the LMN
and MMN which were statistically not different from each other but showed significantly
more AR-ir than women. A similar male-like staining intensity was also found in a
36-yr-old bisexual noncastrated male-to-female transsexual and in a 46-yr-old heterosexual
virilized woman with high circulating levels of testosterone. In all cases studied,
a close relationship was found between the endocrine status and the intensity of
AR staining. High levels of testosterone went together with high nuclear AR-ir and
low levels of testosterone with weak or no nuclear AR-ir. The fact that homosexual
men showed more variability in their nuclear AR-ir profiles compared with heterosexual
men, whereas in the MMN the AR-ir did not differ statistically from the transsexual
group might be due to their acquired immunodeficiency syndrome status, as some of
these patients have subnormal testosterone levels [45]
[46]
[47]
. The strong decrease in nuclear MBC AR-ir in
five old male heterosexual intact subjects also fit the idea of an androgen-dependent
nuclear expression of the AR, as decreased circulating levels of androgens occur
with aging [48]
[49]
. The weak AR-ir in an 84-yr-old man, who was
gynecophilic and who had well documented strong cross-gender identity feelings but
never received hormonal treatment or sex reassignment therapy, fits with his age.
The fact that the 51-yr-old female-to-male transsexual who did not receive testosterone
replacement during the last 3 yr before death still had a female-like pattern of
AR-ir is also fully in agreement with the assumption that circulating testosterone
is crucial for nuclear AR-ir.
From our data there appeared no relationship between AR-ir and sexual orientation
or gender identity. Regardless of sexual orientation or gender identity, a female
pattern of AR-ir, i.e. low nuclear staining in the
LMN and MMN, was observed in women, castrated male-to-female transsexuals, a female-to-male
transsexual, and old men.
Animal studies show that castration induces a shift from strong nuclear to
weak cytoplasmic AR-ir in hypothalamic neurons, which can be reversed by treatment
with androgens [29]
[30]
. Regarding this point it seems of particular
interest to note that ongoing testosterone treatment in female-to-male transsexuals
was accompanied by up-regulation of AR in peripheral ectocervix tissue, resulting
in increased nuclear AR-ir [32]
. In addition to
the specificity tests (Refs. [29]
[36]
[39]
and 43 and our additional specificity data),
the analogy between data on ARs in animals and humans under different levels of testosterone
[33]
[34]
now also seems to provide biological evidence
that in neurons of the human brain, PG21 indeed recognizes ARs. Our data from postmortem
tissue are in agreement with the experimental data reported by Wood and Newman [29]
[30]
, as we also show that gonadectomy in transsexuals
[34]
goes together with cytoplasmic AR-ir, in contrast
with the mainly nuclear AR-ir pattern in the male
Figure 3. Illustration of the almost complete lack of nuclear AR-ir in a noncastrated
old man (A) and in a castrated old man (B). Scale bar,
50 mum.
heterosexual and homosexual group, the noncastrated young transsexual subject,
and the virilized woman who also had strong nuclear AR-ir. These observations support
the concept that the AR occupied by androgens is mainly present in the nucleus, where
it can alter gene expression and regulate cell activity, whereas the unoccupied AR
is for the most part displaced to the cytoplasm [29]
[30]
. The strikingly complete lack of nuclear AR-ir
in the MBC of one male control patient (no. 97101) and in the MMN of two homosexual
patients (no. 87084 and 88087) may be due to their antemortem status with a severely
compromised immune system that may be accompanied by a strong down-regulation of
testosterone levels [45]
[46]
[47]
. In aged males the decreased levels of testosterone
[50]
do not seem to have a strong effect on the
AR in the MBC, as after castration no significant change in AR distribution was noticed.
Hormones and their receptors in relation to sexual orientation and transsexuality
The possible role of steroid hormones in the development of sexual orientation
has been studied in various animal models [51]
and
in humans [52]
. The animal data show that steroid
hormones during the neonatal period contribute to the organization of the brain and
influence sexual preference [53]
. In contrast, the
exposure to sex steroids during adulthood stimulates sexual behavior, but does not
modify sexual orientation in animals or humans [18]
[54]
. In the present study no statistical difference
was found in AR-ir between heterosexual and homosexual men. The lack of differences
in the AR-ir in the posterior hypothalamus and in the sequence variation in the AR
gene [55]
between homosexual and heterosexual men
suggests that neither the intensity of AR-ir nor a variation in AR structure is related
to the expression of homosexuality. Although possible differences between homosexual
and heterosexual men in the AR-ir in other brain areas have not yet been systematically
studied, the data obtained to date reinforce the idea that homosexuality does not
depend on differences in activational effects of testosterone in adulthood [18]
.
In the present study we found no clear relationship between MBC AR-ir and gender
identity as we did, for instance, find for the size of the BSTc and gender identity
[4]
[8]
. Recent studies [56]
[57]
[58]
[59]
and our observation that the volume and neuron
number of the BSTc in male-to-female transsexuals in adulthood is independent of
sex hormone levels [4]
[8]
support the idea that steroids do not act in
adulthood but, rather, earlier during development to establish gender identity.
Functional implications
The results obtained in the present study fully agree with the idea that the
AR-ir sex differences in the MBC of the posterior hypothalamus are due to differences
in circulating levels of androgens and give additional support to the paradigm that
endocrine features during adulthood do not contribute to sexual orientation or gender
identity.
Anatomical and functional studies in rats have shown that the MMN and LMN are
larger in males than in females [60]
, a sex difference
that is accompanied by an increase in the rate of global protein synthesis [61]
.
In addition, experimental data in animals show a sex-specific involvement of the
MB in aspects of sexual behavior such as sexual motivation, penile erection, and
sexual activity [21]
[22]
[23]
[24]
[27]
. Also in humans, the MBC has been implicated
in the regulation of reproduction, possibly by inhibiting the release of gonadotropins,
as lesions in the posterior hypothalamus go together with precocious puberty [62]
.
Our findings of gonadal hormone
TABLE 3 -- Brain material showing nuclear and cytoplasmic androgen receptor labeling
(AR-ir) in the MBC
|
NBB |
Sex |
Age |
Pmd |
Fix |
MMN |
LMN |
Cause of death and clinicopathological
information |
|
N |
C |
N |
C |
|
Young heterosexual men |
|
|
|
|
|
|
|
81-009 |
m |
28 |
23:00 |
32 |
2 |
1 |
2 |
2 |
Medial cerebral artery aneurysm; lung emboli |
|
82-020 |
m |
27 |
41:00 |
40 |
2 |
1 |
2 |
1 |
Drug addiction; sepsis ( S.
aureus); cerebral edema |
|
84-023 |
m |
37 |
39 |
35 |
2 |
0 |
2 |
0 |
Bronchopneumonia |
|
88-017 |
m |
31 |
96:00 |
24 |
1 |
1 |
2 |
1 |
Heart failure due to coronary anomaly (birth defect) |
|
88-035 |
m |
23 |
65:00 |
39 |
1 |
1 |
2 |
2 |
Cardiac arrest |
|
94-040 |
m |
20 |
08:00 |
82 |
2 |
1 |
2 |
0 |
Heart failure and acute fibronous hemorrhagic pneumonia |
|
97-075 |
m |
33 |
18:45 |
-- |
1 |
1 |
2 |
1 |
Brain damage after motor accident |
|
97-083 |
m |
22 |
16:29 |
-- |
2 |
1 |
2 |
2 |
Hypertrophic cardiomyopathy |
|
97-101 |
m |
43 |
09:15 |
-- |
0 |
0 |
0 |
0 |
Aspergillus pneumonia |
|
Mean ± SEM |
29.3 |
35:10 |
42.0 |
|
|
|
|
|
|
|
2.7 |
10:19 |
9.13 |
|
|
|
|
|
|
Young homosexual men |
|
|
|
|
|
|
|
|
86-038 |
m |
37 |
5 |
-- |
2 |
1 |
2 |
1 |
AIDS |
|
86-043 |
m |
42 |
-- |
24 |
2 |
1 |
1 |
1 |
AIDS, disseminated Karposi sarcoma and generalized
mycobacterium avium infections |
|
86-046 |
m |
32 |
49:00 |
11 |
1 |
1 |
1 |
1 |
AIDS, pneumocystic carinii pneumonia |
|
87-030 |
m |
41 |
-- |
40 |
1 |
2 |
2 |
2 |
Respiratory insufficiency |
|
87-084 |
m |
40 |
24:00 |
28 |
0 |
0 |
1 |
1 |
Cerebral (lymfome, fungal infection) |
|
88-087 |
m |
41 |
12:00 |
34 |
0 |
1 |
2 |
2 |
AIDS, bronchopneumonia, cytomegalic infections
and toxoplasmosis |
|
88-121 |
m |
42 |
19:00 |
30 |
2 |
1 |
2 |
1 |
AIDS, cytomegalic meningoencephalitis |
|
89-031 |
m |
25 |
23:00 |
28 |
2 |
1 |
2 |
1 |
AIDS, pneumonia |
|
89-084 |
m |
39 |
-- |
-- |
1 |
1 |
1 |
2 |
AIDS, kaposisarcoma, suicide |
|
89-109 |
m |
32 |
49:00 |
11 |
1 |
1 |
2 |
2 |
AIDS, HIV encephalopathy |
|
Mean ± SEM |
37.1 |
25:51 |
25.75 |
|
|
|
|
|
|
|
1.8 |
6:59 |
3.88 |
|
|
|
|
|
|
Young heterosexual women |
|
|
|
|
|
|
|
|
80-008 |
f |
35 |
08:00 |
26 |
0 |
1 |
1 |
0 |
Acute lymphoblastic leukemia |
|
84-002 |
f |
36 |
86:00 |
51 |
0 |
0 |
0 |
0 |
Multiple fractures; rupture of thoratic aorta |
|
84-026 |
f |
33 |
41:00 |
20 |
0 |
1 |
0 |
1 |
Anoxia, status after resuscitation after progressive
bronchial asthma |
|
85-027 |
f |
29 |
13:00 |
60 |
2 |
1 |
2 |
1 |
Hepatic coma |
|
85-041 |
f |
28 |
05:00 |
44 |
0 |
1 |
2 |
1 |
Cardiogenic shock |
|
86-032 |
f |
33 |
<41:00 |
20 |
0 |
0 |
0 |
0 |
Adenocarcinoma with metastases |
|
92-037 |
f |
32 |
30:00 |
45 |
0 |
0 |
0 |
0 |
Bronchopneumonia/bronchitis |
|
96-410 |
f |
38 |
53:00 |
-- |
1 |
0 |
1 |
1 |
Pneumonia, respiratory insufficiency |
|
Mean ± SEM |
33.0 |
34:38 |
38.0 |
|
|
|
|
|
|
|
1.3 |
10:14 |
6.52 |
|
|
|
|
|
|
Transsexuals |
|
|
|
|
|
|
|
|
|
84-020 |
mtf |
50 |
-- |
30 |
0 |
1 |
0 |
1 |
Suicide |
|
88-064 |
mtf |
43 |
-- |
-- |
1 |
2 |
1 |
2 |
Sarcoma, right side temporal |
|
93-042 |
mtf |
36 |
21:00 |
31 |
2 |
1 |
2 |
1 |
Pneumonia after CMV and pseudomonas aeruinosa infection |
|
93-070 |
mtf |
53 |
96:00 |
34 |
0 |
0 |
0 |
0 |
Acute fatty liver (due to alcohol abuse) |
|
95-018 |
mtf |
48 |
24:00 |
36 |
2 |
1 |
2 |
1 |
Cardiac arrest |
|
98-137 |
mtf |
26 |
-- |
40 |
0 |
0 |
0 |
0 |
Suicide: XTC overdose |
|
98-138 |
ftm |
51 |
04:15 |
32 |
1 |
2 |
1 |
2 |
Cachexia |
|
98-141 |
mtf |
74 |
06:35 |
33 |
0 |
1 |
0 |
1 |
Recent multiple cerebral infarction, cardiac failure,
pneumonia |
|
Mean ± SEM |
47.6 |
30:22 |
33.7 |
|
|
|
|
|
|
|
5.3 |
18:51 |
1.4 |
|
|
|
|
|
|
Old heterosexual, castrated men |
|
|
|
|
|
|
|
89-103 |
m |
67 |
24:00 |
28 |
0/1 |
0/1 |
0/1 |
0/1 |
Carcinoma of pancreas with multiple metastases;
cachexia |
|
94-090 |
m |
86 |
03:00 |
93 |
0/1 |
0/1 |
0/1 |
0/1 |
Septic shock with lung and prostate carcinoma |
|
94-109 |
m |
82 |
05:35 |
32 |
0 |
0/1 |
0 |
0/1 |
Respiratory insufficiency: prostate carcinoma; orchiectomy;
renal insufficiency |
|
95-062 |
m |
80 |
04:30 |
24 |
0 |
0/1 |
0 |
0/1 |
Renal insufficiency with metabolic acidosis and
hyperkalemia |
|
97-157 |
m |
69 |
05:55 |
45 |
0 |
0/1 |
0 |
0/1 |
Serious prostate cancer with metastasis |
|
Mean ± SEM |
76.8 |
8:02 |
44.4 |
|
|
|
|
|
|
|
4.2 |
4:31 |
14.1 |
|
|
|
|
|
|
Old heterosexual men |
|
|
|
|
|
|
|
|
80-005 |
m |
70 |
17:00 |
-- |
0/1 |
0/1 |
0/1 |
0/1 |
Pneumonia |
|
82-005 |
m |
68 |
05:45 |
30 |
0/1 |
0/1 |
0/1 |
0/1 |
Myocardial infarction; glomerulosclerosis of kidneys |
|
93-019 |
m |
78 |
-- |
70 |
0/1 |
0/1 |
0/1 |
0/1 |
Cardiopulmonary insufficiency; bronchopneumonia |
|
93-039 |
m |
79 |
3:00 |
53 |
0 |
0/1 |
0 |
0/1 |
Internal bleeding; decompensatio cordis |
|
97-039 |
m |
87 |
4:00 |
45 |
0/1 |
0/1 |
0/1 |
0/1 |
Myocardial infarction |
|
Mean ± SEM |
76.4 |
7:26 |
49.5 |
|
|
|
|
|
|
|
3.8 |
3:44 |
9.6 |
|
|
|
|
|
|
Untreated transsexual |
|
|
|
|
|
|
|
|
96-088 |
m |
84 |
41:00 |
38 |
0 |
0/1 |
0 |
0/1 |
Small cell carcinoma of the lungs with metastasis
to the liver |
|
Virilized syndrome |
|
|
|
|
|
|
|
|
|
83-004 |
f |
46 |
6:00 |
34 |
2 |
1 |
2 |
1 |
Adrenocortical carcinoma; postoperative hemorrhage |
|
m, Male; f, female; mtf, male-to-female
transsexual; ftm, female to male transsexual. |
receptors in neurons of the MBC underline the possibility
of its involvement in reproduction.
In addition to reproduction, the MBC plays a crucial role in memory function
[63]
. Mamillary bodies atrophy with age [64]
and even more so in Alzheimer's disease [65]
and
are damaged in alcohol-associated Wernicke-Korsakoff's disease [66]
.
The decline with age in nuclear AR-ir in the male MBC as found in the present study
may also be reflected in functional changes. Whether the observed changes in the
MBC play a role in the relationship between low levels of sex hormones and impairment
in sexual and cognitive functioning [48]
[67]
[68]
or in the increased prevalence of nonfamiliar
Alzheimer's disease in the elderly [69]
[70]
should be further investigated. Protective
actions of androgens on neurons [71]
and memory
loss [72]
[73]
have been described. It may in this connection
also be of interest to investigate the possible neuroprotective effects of androgens
in age-related diseases in men, in a similar way as is done for estrogen replacement
therapy in postmenopausal women with reported beneficial effects on physical status,
mood, cognition, and the prevention of Alzheimer's disease [67]
[74]
[75]
, although the latter certainly requires more
investigation.
In conclusion, here we show for the first time that the sex differences in
nuclear AR-ir in the MBC of the posterior hypothalamus reflect differences in circulating
levels of androgens rather than differences in sexual orientation or gender identity.
The functional implications of these alterations should be studied in the future.
Acknowledgments
Brain material was obtained from The Netherlands Brain Bank (Anne Holtrop,
Michiel Kooreman, and Jose Wouda; coordinator Dr. R. Ravid). We thank Bart
Fisser for his technical assistance, Dr. F. W. van Leeuwen for the antibody PG21,
Dr. S. Kaiser for critically reading the manuscript, G. van der Meulen for photography,
and W. Verweij for secretarial help.
References
1.
Kawata M. 1995 Roles
of steroid hormones and their receptors in structural organization in the nervous
system. Neurosci Res. 24:1-46.
Abstract
2.
Beyer C. 1999 Estrogen
and the developing mammalian brain. Anat Embryol. 199:379-390.
Abstract
3.
Swaab DF, Hofman MA.
1995 Sexual differentiation of the human hypothalamus in relation to gender and sexual
orientation. Trends Neurosci. 18:264-270.
Abstract
4.
Kruijver FP, Zhou JN, Pool CW,
Hofman MA, Gooren LJG, Swaab DF. 2000 Male-to-female transsexuals have
female neuron numbers in a limbic nucleus. J Clin Endocrinol Metab. 85:2034-2041.
Full Text
5.
Swaab DF. 1997 Neurobiology
and neuropathology of the human hypothalamus. In: Bloom FE, Bjorklund A, Hokfelt
T, eds. Handbook of chemical neuroanatomy, vol 13, part 1. Amsterdam: Elsevier; 39-137.
6.
Swaab DF. 1995 Development
of the human hypothalamus. Neurochem Res. 20:509-519.
Abstract
7.
Ishunina TA, Salehi A, Hofman
MA, Swaab DF. 1999 Activity of vasopressinergic neurons of the human supraoptic
nucleus is age- and sex-dependent. J Neuroendocrinol. 11:251-258.
Abstract
8.
Zhou JN, Hofman MA, Gooren LJG,
and Swaab DF. 1995 A sex difference in the human brain and its relation
to transsexuality. Nature. 378:68-70.
Abstract
9.
Swaab DF, Fliers E.
1985 A sexually dimorphic nucleus in the human brain. Science. 228:1112-1115.
Abstract
10.
Byne W, Lasco LB, Shinwari
A, Edgar MA, Morgello S, Jones LB, Tobet S. 2000 The interstitial nuclei
of the human anterior hypothalamus: an investigation of sexual variation in volume
and cell size, number and density. Brain Res. 254-258.
11.
Allen LS, Hines M, Shryne JE,
Gorski RA. 1989 Sex differences in the bed nucleus of the stria terminalis
of the human brain. J Comp Neurol. 302:697-706.
12.
Swaab DF, Zhou JN, Ehlhart
T, Hofman MA. 1994 Development of vasoactive intenstinal polypeptide (VIP)
neurons in the human suprachiasmatic nucleus (SCN) in relation to birth and sex.
Dev Brain Res. 79:249-259.
13.
Zhou JN, Hofman MA, Swaab DF.
1995 VIP neurons in the human SCN in relation to sex, age, and Alzheimer's disease.
Neurobiol Aging. 16:571-576.
Abstract
14.
Allen LS, Gorski RA.
1991 Sexual dimorphism of the anterior commissure and massa intermedia of the human
brain. J Comp Neurol. 312:97-104.
Abstract
15.
Swaab DF, Hofman MA.
1990 An enlarged suprachiasmatic nucleus in homosexual men. Brain Res. 537:141-148.
Abstract
16.
Allen LS, Gorski RA.
1992 Sexual orientation and the size of the anterior commissure in the human brain.
Proc Natl Acad Sci USA. 89:7199-7202.
Abstract
17.
LeVay S. 1991 A
difference in hypothalamic structure between heterosexual and homosexual men. Science.
235:1034-1037.
Abstract
18.
Buvat J, Lemaire A, Ratajczyk
J. 1996 Role of hormones in sexual dysfunctions, homosexuality, transsexualism
and deviant sexual behavior: diagnostic and therapeutic consequences. Contracept
Fertil Sex. 24:834-846.
Abstract
19.
Gooren LJG. 1990
The endocrinology of transsexualism: a review and commentary. Psychoneuroendocrinology.
15:3-14.
Abstract
20.
Fernandez-Guasti A,
Kruijver FPM, Fodor M, Swaab DF. 2000 Sex differences in the distribution
of androgen receptors in the human hypothalamus J Comp Neurol 425:422-435.
Abstract
21.
Soulairac ML. 1963
Etude experimentale des regulations hormononerveuses du comportment sexuel du rat
male. Ann Endocrinol. 24(Suppl):1-94.
22.
MacLean PD, Ploog D.
1962 Cerebral representation of penile erection. J Neurophysiol. 25:29-55.
23.
Poeck K, Pilleri G.
1965 Release of hypersexual behaviour due to lesion in the limbic system. Acta Neurol
Scand. 41:233-244.
24.
Lisk RD. 1967 Neural
localization for androgen activation of copulatory behavior in the male rat. Endocrinology.
80:754-761.
Citation
25.
Michael RP, Rees HD, Bonsall
RW. 1989 Sites in the male primate brain at which testosterone acts as
an androgen. Brain Res. 502:11-20.
Abstract
26.
Clancy AN, Bonsall RW, Michael
RP. 1992 Immunocytochemical labeling of androgen receptors in the brain
of rat and monkey. Life Sci. 50:409-417.
Abstract
27.
Galindo-Estaun I.
1983 Effect of mamillary body lesions in adult rats on the survival and development
of their young. Rev Esp Fisiol. 39:447-454.
Abstract
28.
Menard CS, Harlan RE.
1993 Up-regulation of androgen receptor immunoreactivity in the rat brain by androgenic-anabolic
steroids. Brain Res. 622:226-236.
Abstract
29.
Wood RI, Newman SW.
1993 Intracellular partitioning of androgen receptor immunoreactivity in the brain
of the male Syrian hamster: effects of castration and steroid replacement. J Neurobiol.
24:925-938.
Abstract
30.
Wood RI, Newman SW.
1999 Androgen receptor immunoreactivity in the male and female Syrian hamster brain.
J Neurobiol. 39:359-370.
Abstract
31.
Lu SF, McKenna SE, Cologer-Clifford
A, Nau EA, Simon NG. 1998 Androgen receptor in mouse brain: sex differences
and similarities in autoregulation. Endocrinology. 139:1594-1601.
Abstract
32.
van der Kwast TH, Dommerholt
HB, van Vroonhoven CC, Chadha S. 1994 Androgen receptor expression in
the cervix of androgen-treated female-to male transsexuals: association with morphology
and chain-specific keratin expression. Int J Gynecol Pathol. 13:133-138.
Abstract
33.
Winter JD. 1978
Prepubertal and pubertal endocrinology. In: Falkner F, Tanner, JM, eds. Human growth,
vol 2. New York: Plenum Press.
34.
Giltay EJ, Lambert J, Gooren
LJG, Elbers JMH, Steyn M, Stehouwer CDA. 1999 Sex steroids, insulin, and
arterial stiffness in women and men. Hypertension. 34:590-597.
Abstract
35.
Shi SHR, Chaiwun B, Young L,
Cote RJ, Taylor CIR. 1993 Antigen retrieval technique utilizing citrate
buffer or urea solution for immunohistochemical demonstration of androgen receptor
in formalin-fixed paraffin sections. J Histochem Cytochem. 41:1599-1604.
Abstract
36.
Puy L, MacLusky NJ, Becker
L, Karzan N, Trachtenberg J, Brown TJ. 1995 Immunocytochemical detection
of androgen receptor in human temporal cortex: characterization and application of
polyclonal androgen receptor antibodies in frozen and paraffin embedded tissues.
J Steroid Biochem Mol Biol. 55:197-209.
Abstract
37.
Adams JC. 1992 Biotin
amplification of biotin and horseradish peroxidase signals in histochemical stains.
J Histochem Cytochem. 40:1457-1463.
Abstract
38.
Mai JK, Assheuer J, Paxinos
G. 1997 Atlas of the human brain. London: Academic Press.
39.
Prins GS, Birsch L, Greene
GL. 1991 Androgen receptor localization in different cell types of the
adult rat prostate. Endocrinology. 129:3187-3199.
Abstract
40.
Michael RP, Clancy AN, Zumpe
D. 1995 Distribution of androgen receptor-like immunoreactivity in the
brains of cymonologus monkeys. J Neuroendocrinol. 7:713-719.
Abstract
41.
Janssen PJ, Brinkmann AO, Boersma
WJ, van der Kwast TH. 1994 Immunohistochemical detection of the androgen
receptor with monoclonal antibody F39.4 in routinely processed paraffin-embedded
human tissues after microwave pre-treatment. J Histochem Cytochem. 42:1169-1175.
Abstract
42.
Sar M, Lubahn DB, French FS,
Wilson EM. 1990 Immunocytochemical localization of the androgen receptor
in rat and human tissues. Endocrinology. 127:3180-3186.
Abstract
43.
Iqbal J, Swanson JJ, Prins
GS, Jacobson CD. 1995 Androgen receptor-like immunoreactivity in the Brazilian
opossum brain and pituitary: distribution and effects of castration and testosterone
replacement in the adult male. Brain Res. 703:1-18.
Abstract
44.
van der Sluis PJ, Pool CW,
Sluiter AA. 1988 Immunochemical detection of
peptides
and proteins on press-blots after direct tissue gel isoelectric focusing. Electrophoresis.
9:654-661.
Abstract
45.
Greenspoon S, Corcoran C, Askari
H, et al. 1998 Effects of androgen administration in men with the AIDS
wasting syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern
Med. 129:18-26.
Citation
46.
Dobs AS, Few WL 3 rd
,
Blackman MR, Harman SM, Hoover DR, Graham NM. 1996 Serum hormones in men
with human immunodeficiency virus-associated wasting. J Clin Endocrinol Metab. 81:4108-4112.
Full Text
47.
Sellmeyer DE, Grunfeld C.
1996 Endocrine and metabolic disturbances in human immunodeficiency virus infection
and the acquired immune deficiency syndrome. Endocr Rev. 17:518-532.
Abstract
48.
Seidman SN, Walsch BT.
1999 Testosterone and depression in ageing men. Am J Geriatr Psychiatry. 7:18-33.
Abstract
49.
Sternbach H. 1998
Age-associated testosterone decline in men: clinical issues for psychiatry. Am J
Psychiatry. 155:1310-1318.
Abstract
50.
Vermeulen A, Kaufman JM, Giagulli
VA. 1996 Influence of some biological indexes on sex hormone-binding globulin
and androgen levels in ageing or obese males. J Clin Endocrinol Metab. 81:1821-1826.
Full Text
51.
Adkins-Regan E.
1988 Sex hormones and sexual orientation in animals. Psychobiology. 16:335-347.
52.
Meyer-Bahlburg HFL, Ehrhardt
AA, Rosen LR, et al. 1995 Prenatal estrogens and the development of homosexual
orientation. Dev Psychol. 31:12-21.
53.
Swaab DF, Slob AK, Houtsmuller
EJ, Brand T, Zhou JN. 1995 Increased number of vasopressin neurons in
the suprachiasmatic nucleus (SCN) of "bisexual" adult male rats following perinatal
treatment with the aromatase blocker ATD. Dev Brain Res. 85:273-279.
54.
Meyer-Bahlburg HFL.
1984 Psychoendocrine research on sexual orientation: current status and future options
in progress. Brain Res. 71:375-397.
55.
Macke JP, Hu N, Hu S, et al.
1993 Sequence variation in the androgen receptor gene is not a common determinant
of male sexual orientation. Am J Hum Genet. 53:844-852.
Abstract
56.
Diamond M, Sigmundson HK.
1997 Sex reassignment at birth. Arch Pediatr Adolesc Med. 151:298-304.
Abstract
57.
Gooren L, Cohen-Kettenis PT.
1991 Development of male gender identity/role and a sexual orientation towards women
in a 46,XY subject with and incomplete form of the androgen insensitivity syndrome.
Arch Sex Behav. 20:459-470.
Abstract
58.
Birnbacher R, Marberger M,
Weissenbacher G, Schober E, Frisch H. 1999 Gender identity reversal in
an adolescent with mixed gonadal dysgenesis. J Pediatr Endocrinol Metab. 12:687-690.
Abstract
59.
Dessens AB, Cohen-Kettenis
PT, Mellenbergh GJ, van de Poll N, Koppe JG. 1999 Prenatal exposure to
anticonvulsants and psychosexual development. Arch Sex Behav. 28:31-44.
Abstract
60.
Lopez L, Brana M, Burgos P,
Arias JL. 1994 Structural dimorphism in the mammillary bodies of the rat.
Neurosci Lett. 176:197-200.
Abstract
61.
Gonzalez-Gonzalez S, Gonzalez-Pardo
H, Vallejo G, Arias JL. 1996 Functional sexual differences in rat mammillary
bodies: a quantitative AG-NOR study. Acta Anat. 157:205-209.
Abstract
62.
Bauer HG. 1954 Endocrine
and other clinical manifestations of hypothalamic disease. J Clin Endocrinol. 14:13-31.
63.
Tanaka Y, Miyazawa Y, Akaoka
F, Yamada T. 1997 Amnesia following damage to the mammillary bodies. Neurology.
48:160-165.
Full Text
64.
Raz N, Torres IJ, Acker JD.
1992 Age-related shrinkage of the mamillary bodies: in vivo
MRI evidence. NeuroReport. 3:713-716.
65.
McDuff T, Sumi SM.
1985 Subcortical degeneration in Alzheimer's disease. Neurology. 35:123-126.
Abstract
66.
Kopelman MD. 1995
The Korsakoff syndrome. Br J Psychiatry. 166:154-173.
Abstract
67.
McEwen BS. 1999
The molecular and neuroanatomical basis for estrogen effects in the central nervous
system. J Clin Endocrinol Metab. 84:1790-1797.
Full Text
68.
Yaffe K, Lui LY, Grady D, Cauly
J, Kramer J, Cummings SR. 2000 Cognitive decline in women in relation
to non-protein-bound oestradiol concentrations. Lancet. 356:708-712.
69.
Henderson VW. 1997
The epidemiology of estrogen replacement therapy and Alzheimer's disease. Neurology.
48:S27-S35.
70.
Lerner AJ. 1999
Women and Alzheimer's disease. J Clin Endocrinol Metab. 84:1830-1834.
71.
Ahlblom E, Grandison L, Bonfoco
E, Zhivotovsky B, Ceccatelli S. 1999 Androgen treatment of neonatal rats
decreases susceptibility of cerebellar granule neurons to oxidative stress in
vitro. Eur J Neurosci. 11:1285-1291.
72.
Adinof B, Martin PR, Eckardt
MJ, Linnoila M. 1993 Role of DHEA and DHEA-S in Alzheimer disease. Am
J Psychiatry. 150:1432-1433.
73.
Carlson LE, Sherwin BB, Chertkow
HM. 1999 Relationships between dehy droepiandrosterone sulfate (DHEAS)
and cortisol (CRT) plasma levels and everyday memory in Alzheimer's disease patients
compared to healthy controls. Horm Behav. 35:254-263.
74.
Ohkura T, Isse K, Akazawa K,
Hamamoto M, Yaoi Y, Hagino N. 1994 Evaluation of estrogen treatment in
female patients with dementia of the Alzheimer type. Endocr J. 41:361-371.
75.
Tang MX, Jacobs D, Stern Y,
et al. 1996 Effect of oestrogen during menopause on risk and age at onset
of Alzheimer's disease. Lancet. 348:429-432.